Equibles does not estimate personal net worth.
Get an email with a short summary when Halozyme Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get HALO alertsNicole LaBrosse is recorded as CFO at Halozyme Therapeutics, Inc. (HALO). The proxy statement of Halozyme Therapeutics, Inc. reports total compensation of $4,578,814 for Nicole LaBrosse in fiscal 2025, including a base salary of $604,188. Disclosed compensation is on record for 4 fiscal years. Nicole LaBrosse has spoken on 16 earnings calls and 2 other investor events across 1 company, most recently for Halozyme Therapeutics, Inc. on January 28, 2026. Halozyme Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Halozyme Therapeutics, Inc. includes Helen Torley (CEO and Board Member), Darren Snellgrove (CFO), Elaine D. Sun (CFO) and 7 others.
“Yeah, as Helen mentioned, we are pleased that we're able to give this multi-year view that, again, many companies don't do. And this is because we really focus on the 10 products that are globally approved today.”
“Our strong third quarter performance continues to reflect the momentum of our core enhanced technology. Total quarterly revenues grew by approximately 22% to $354 million, with royalty revenue increasing 52% to $236 million.”
“Our outperformance in the second quarter reflects the growing momentum in the business, supporting another raise to our 2025 financial guidance. Total quarterly revenue increased by 41%, with $206 million in royalty revenue increasing 65%.”
“The first quarter of 2025 represented a strong start to the year, and we're excited to raise our full-year expectations based on these strong results.”
“We grew total revenue by 22% and beat our guidance, which we increased twice during the year, and helped us grow non-GAAP EPS by 53%. With our bottom line growth outpacing the top line due to our high margin royalty revenue, we converted 74% of our adjusted EBITDA into free cash flow, representing $468 million.”
Start not stated–2026-03-30
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Halozyme Therapeutics, Inc. (HALO) | Senior Vice President, Chief Financial Officer | $604,188 | $4,578,814 |
| 2024 | Halozyme Therapeutics, Inc. (HALO) | Senior Vice President, Chief Financial Officer | $568,188 | $4,218,276 |
| 2023 | Halozyme Therapeutics, Inc. (HALO) | Senior Vice President, Chief Financial Officer | $546,188 | $3,849,419 |
| 2022 | Halozyme Therapeutics, Inc. (HALO) | Senior Vice President, Chief Financial Officer | $467,836 | $2,683,103 |
